Dr. Tahseen Mozaffar is a Professor of Neurology and Pathology and Laboratory Medicine and the
former Founding Director of the Division of Neuromuscular Disorders. Dr. Mozaffar serves as chair of
one of the biomedical committees and is the Associate Director for the Center for Translational Sciences
Award (CTSA) at University of California, Irvine. He was the Principal Investigator for UCI-NEXT, the
NeuroNEXT award to the University of California, Irvine, one of 25 such NeuroNEXT sites funded by
the NINDS/NIH. He is also the Lead Investigator for a multicenter NIH/NIAMS funded Natural History
Study in sIBM (INSPIRE-IBM), which started April 2021.
He graduated medical school at the Aga Khan University in Karachi, Pakistan in 1989 and trained in
Neurology and Neuromuscular Disorders at Washington University/Barnes Hospital in St. Louis, MO.
Dr. Mozaffar has been at UC Irvine since 2000 where he has built an internationally recognized clinical
and research program in Neuromuscular Disorders.
He is actively involved in clinical and translational research in Neuromuscular Disorders, including
currently serving as Principal Site Investigator on over a dozen clinical trials in myasthenia gravis, rare
and ultra-rare myopathies and in immune myopathies. He has co-authored over 250 peer-reviewed
publications and has authored or co-authored over a dozen book chapters and invited reviews. As an
expert in these rare and ultra-rare myopathies, he is actively sought as an advisor by pharmaceutical
companies for trial design and identifying disease targets.
He is the Director of the nationally recognized Annual UC Irvine Neuromuscular Colloquium, now in its
15 th year of existence and the founding Director of the Annual Neuromuscular Pathology Colloquium,
now in its 10 th year.
Cure Rare Disease, a non-profit organization (Tax ID number 82-2473513), is qualified as a tax-exempt organization under section 501(c)(3) of the IRS and has been designated as a “public charity” under section 170.
